Cdh5(PAC)-CreERT2 Mouse

Random Transgenic

Cdh5(PAC)-CreERT2 Random Transgenic Mouse Model

C57BL/6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 13073-F
    tg/wt
    C57BL/6-Tg(Cdh5-cre/ERT2)1Rha
  • 13073-M
    tg/wt
    C57BL/6-Tg(Cdh5-cre/ERT2)1Rha
  • An inducible cre deleter under the control of the vascular endothelial cadherin (Cdh5(PAC)) promoter
  • Cre recombination is inducible via administration of tamoxifen
  • Useful for study of angiogenesis, atherosclerosis and neovascularization
  • Non-induced Cdh5(PAC)-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Cdh5(PAC)-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in vascular endothelial cells (95%+).
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin:

The Cdh5(PAC)-CreERT2 Mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Cdh5(PAC) promoter fragment fused to a CreERT2 cDNA into C57BL/6 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2013.

Source:

Sponsor: Cancer Research Technology

Availability:

Limited quantities of breeders are available for purchase after execution of a license.

Ordering Note: Animals ordered at 4 weeks of age require rapid genotyping and a $40.00 per mouse charge will be added.

Color:

Black

Species:

Mouse

Initial Publication:

Sörensen I, Adams RH, Gossler A. (2009) DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. Blood. 113(22):5680-8.


Access to this model requires execution of a Limited Breeding Agreement. The current agreement fees are:
  • $3,000/€2550 per year for non-profit users
  • $10,000/€8500 per year for for-profit users
Once the agreement is executed, you may order mice for use in breeding and crossbreeding. Please contact Taconic Customer Service for details.

Purchase of line #13073 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.